Eli Lilly, a leading pharmaceutical company, reported impressive fourth-quarter and full-year 2024 results, driven by robust sales of its highly anticipated weight-loss and diabetes drugs, Zepbound and Mounjaro.

The company's stock surged in pre-market trading as it exceeded Wall Street's expectations and provided an optimistic outlook for 2025, fueled by the continued momentum of these groundbreaking medications.

In the fourth quarter, Eli Lilly's revenue soared 45% year-over-year to $13.53 billion, propelled by a remarkable 60% increase in Mounjaro sales to $3.53 billion and a staggering increase in Zepbound sales to $1.91 billion, compared to $175.8 million a year earlier. These blockbuster drugs, which target the growing obesity and diabetes markets, have been instrumental in driving Eli Lilly's strong financial performance.

For the full year 2024, Eli Lilly reported revenue of $45.04 billion, a 32% increase from the previous year, underscoring the significant impact of Zepbound and Mounjaro on the company's top line.

Looking ahead, Eli Lilly provided an optimistic outlook for 2025, forecasting revenue between $58 billion and $61 billion, representing a potential growth of up to 35.5% year-over-year. The company expects its adjusted earnings per share to range from $22.50 to $24.00, surpassing analysts' expectations and reflecting the continued demand for its weight-loss and diabetes treatments.